IMMUNE RESPONSE AND SURVIVAL OF REFRACTORY CANCER PATIENTS WHO RECEIVED TGF-Β2 ANTISENSE/GM-CSF GENE MODIFIED AUTOLOGOUS TUMOR CELL (TAG) VACCINE

Friday, July 26, 2013

Read the Story Here

Related Posts

Discover more posts like this.

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Oct 25, 2024

Dr. Minal Barve

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Oct 14, 2024

Dr. Minal Barve

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider
See All Posts